Hypertension susceptibility loci and blood pressure response to antihypertensives: Results from the pharmacogenomic evaluation of antihypertensive responses study

Yan Gong, Caitrin W. McDonough, Zhiying Wang, Wei Hou, Rhonda M. Cooper-DeHoff, Taimour Y. Langaee, Amber L. Beitelshees, Arlene B. Chapman, John G. Gums, Kent R Bailey, Eric Boerwinkle, Stephen T Turner, Julie A. Johnson

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background-To date, 39 single nucleotide polymorphisms (SNPs) have been associated with blood pressure (BP) or hypertension in genome-wide association studies in whites. Our hypothesis is that the loci/SNPs associated with BP/hypertension are also associated with BP response to antihypertensive drugs. Methods and Results-We assessed the association of these loci with BP response to atenolol or hydrochlorothiazide monotherapy in 768 hypertensive participants in the Pharmacogenomics Responses of Antihypertensive Responses study. Linear regression analysis was performed on whites for each SNP in an additive model adjusting for baseline BP, age, sex, and principal components for ancestry. Genetic scores were constructed to include SNPs with nominal associations, and empirical P values were determined by permutation test. Genotypes of 37 loci were obtained from Illumina 50K cardiovascular or Omni1M genome-wide association study chips. In whites, no SNPs reached Bonferroni-corrected a of 0.0014, 6 reached nominal significance (P<0.05), and 3 were associated with atenolol BP response at P<0.01. The genetic score of the atenolol BP-lowering alleles was associated with response to atenolol (P=3.3×10-6 for systolic BP; P=1.6×10-6 for diastolic BP). The genetic score of the hydrochlorothiazide BP-lowering alleles was associated with response to hydrochlorothiazide (P=0.0006 for systolic BP; P=0.0003 for diastolic BP). Both risk score P values were <0.01 based on the empirical distribution from the permutation test. Conclusions-These findings suggest that selected signals from hypertension genome-wide association studies may predict BP response to atenolol and hydrochlorothiazide when assessed through risk scoring.

Original languageEnglish (US)
Pages (from-to)686-691
Number of pages6
JournalCirculation: Cardiovascular Genetics
Volume5
Issue number6
DOIs
StatePublished - Dec 2012

Fingerprint

Pharmacogenetics
Antihypertensive Agents
Blood Pressure
Hypertension
Atenolol
Hydrochlorothiazide
Single Nucleotide Polymorphism
Genome-Wide Association Study
Alleles

Keywords

  • β-blocker
  • Blood pressure
  • Diuretics
  • Hypertension
  • Pharmacogenetics
  • Polymorphisms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Genetics(clinical)
  • Genetics

Cite this

Hypertension susceptibility loci and blood pressure response to antihypertensives : Results from the pharmacogenomic evaluation of antihypertensive responses study. / Gong, Yan; McDonough, Caitrin W.; Wang, Zhiying; Hou, Wei; Cooper-DeHoff, Rhonda M.; Langaee, Taimour Y.; Beitelshees, Amber L.; Chapman, Arlene B.; Gums, John G.; Bailey, Kent R; Boerwinkle, Eric; Turner, Stephen T; Johnson, Julie A.

In: Circulation: Cardiovascular Genetics, Vol. 5, No. 6, 12.2012, p. 686-691.

Research output: Contribution to journalArticle

Gong, Y, McDonough, CW, Wang, Z, Hou, W, Cooper-DeHoff, RM, Langaee, TY, Beitelshees, AL, Chapman, AB, Gums, JG, Bailey, KR, Boerwinkle, E, Turner, ST & Johnson, JA 2012, 'Hypertension susceptibility loci and blood pressure response to antihypertensives: Results from the pharmacogenomic evaluation of antihypertensive responses study', Circulation: Cardiovascular Genetics, vol. 5, no. 6, pp. 686-691. https://doi.org/10.1161/CIRCGENETICS.112.964080
Gong, Yan ; McDonough, Caitrin W. ; Wang, Zhiying ; Hou, Wei ; Cooper-DeHoff, Rhonda M. ; Langaee, Taimour Y. ; Beitelshees, Amber L. ; Chapman, Arlene B. ; Gums, John G. ; Bailey, Kent R ; Boerwinkle, Eric ; Turner, Stephen T ; Johnson, Julie A. / Hypertension susceptibility loci and blood pressure response to antihypertensives : Results from the pharmacogenomic evaluation of antihypertensive responses study. In: Circulation: Cardiovascular Genetics. 2012 ; Vol. 5, No. 6. pp. 686-691.
@article{2def0267777445b1a9fc10b457029435,
title = "Hypertension susceptibility loci and blood pressure response to antihypertensives: Results from the pharmacogenomic evaluation of antihypertensive responses study",
abstract = "Background-To date, 39 single nucleotide polymorphisms (SNPs) have been associated with blood pressure (BP) or hypertension in genome-wide association studies in whites. Our hypothesis is that the loci/SNPs associated with BP/hypertension are also associated with BP response to antihypertensive drugs. Methods and Results-We assessed the association of these loci with BP response to atenolol or hydrochlorothiazide monotherapy in 768 hypertensive participants in the Pharmacogenomics Responses of Antihypertensive Responses study. Linear regression analysis was performed on whites for each SNP in an additive model adjusting for baseline BP, age, sex, and principal components for ancestry. Genetic scores were constructed to include SNPs with nominal associations, and empirical P values were determined by permutation test. Genotypes of 37 loci were obtained from Illumina 50K cardiovascular or Omni1M genome-wide association study chips. In whites, no SNPs reached Bonferroni-corrected a of 0.0014, 6 reached nominal significance (P<0.05), and 3 were associated with atenolol BP response at P<0.01. The genetic score of the atenolol BP-lowering alleles was associated with response to atenolol (P=3.3×10-6 for systolic BP; P=1.6×10-6 for diastolic BP). The genetic score of the hydrochlorothiazide BP-lowering alleles was associated with response to hydrochlorothiazide (P=0.0006 for systolic BP; P=0.0003 for diastolic BP). Both risk score P values were <0.01 based on the empirical distribution from the permutation test. Conclusions-These findings suggest that selected signals from hypertension genome-wide association studies may predict BP response to atenolol and hydrochlorothiazide when assessed through risk scoring.",
keywords = "β-blocker, Blood pressure, Diuretics, Hypertension, Pharmacogenetics, Polymorphisms",
author = "Yan Gong and McDonough, {Caitrin W.} and Zhiying Wang and Wei Hou and Cooper-DeHoff, {Rhonda M.} and Langaee, {Taimour Y.} and Beitelshees, {Amber L.} and Chapman, {Arlene B.} and Gums, {John G.} and Bailey, {Kent R} and Eric Boerwinkle and Turner, {Stephen T} and Johnson, {Julie A.}",
year = "2012",
month = "12",
doi = "10.1161/CIRCGENETICS.112.964080",
language = "English (US)",
volume = "5",
pages = "686--691",
journal = "Circulation. Genomic and precision medicine",
issn = "1942-325X",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "6",

}

TY - JOUR

T1 - Hypertension susceptibility loci and blood pressure response to antihypertensives

T2 - Results from the pharmacogenomic evaluation of antihypertensive responses study

AU - Gong, Yan

AU - McDonough, Caitrin W.

AU - Wang, Zhiying

AU - Hou, Wei

AU - Cooper-DeHoff, Rhonda M.

AU - Langaee, Taimour Y.

AU - Beitelshees, Amber L.

AU - Chapman, Arlene B.

AU - Gums, John G.

AU - Bailey, Kent R

AU - Boerwinkle, Eric

AU - Turner, Stephen T

AU - Johnson, Julie A.

PY - 2012/12

Y1 - 2012/12

N2 - Background-To date, 39 single nucleotide polymorphisms (SNPs) have been associated with blood pressure (BP) or hypertension in genome-wide association studies in whites. Our hypothesis is that the loci/SNPs associated with BP/hypertension are also associated with BP response to antihypertensive drugs. Methods and Results-We assessed the association of these loci with BP response to atenolol or hydrochlorothiazide monotherapy in 768 hypertensive participants in the Pharmacogenomics Responses of Antihypertensive Responses study. Linear regression analysis was performed on whites for each SNP in an additive model adjusting for baseline BP, age, sex, and principal components for ancestry. Genetic scores were constructed to include SNPs with nominal associations, and empirical P values were determined by permutation test. Genotypes of 37 loci were obtained from Illumina 50K cardiovascular or Omni1M genome-wide association study chips. In whites, no SNPs reached Bonferroni-corrected a of 0.0014, 6 reached nominal significance (P<0.05), and 3 were associated with atenolol BP response at P<0.01. The genetic score of the atenolol BP-lowering alleles was associated with response to atenolol (P=3.3×10-6 for systolic BP; P=1.6×10-6 for diastolic BP). The genetic score of the hydrochlorothiazide BP-lowering alleles was associated with response to hydrochlorothiazide (P=0.0006 for systolic BP; P=0.0003 for diastolic BP). Both risk score P values were <0.01 based on the empirical distribution from the permutation test. Conclusions-These findings suggest that selected signals from hypertension genome-wide association studies may predict BP response to atenolol and hydrochlorothiazide when assessed through risk scoring.

AB - Background-To date, 39 single nucleotide polymorphisms (SNPs) have been associated with blood pressure (BP) or hypertension in genome-wide association studies in whites. Our hypothesis is that the loci/SNPs associated with BP/hypertension are also associated with BP response to antihypertensive drugs. Methods and Results-We assessed the association of these loci with BP response to atenolol or hydrochlorothiazide monotherapy in 768 hypertensive participants in the Pharmacogenomics Responses of Antihypertensive Responses study. Linear regression analysis was performed on whites for each SNP in an additive model adjusting for baseline BP, age, sex, and principal components for ancestry. Genetic scores were constructed to include SNPs with nominal associations, and empirical P values were determined by permutation test. Genotypes of 37 loci were obtained from Illumina 50K cardiovascular or Omni1M genome-wide association study chips. In whites, no SNPs reached Bonferroni-corrected a of 0.0014, 6 reached nominal significance (P<0.05), and 3 were associated with atenolol BP response at P<0.01. The genetic score of the atenolol BP-lowering alleles was associated with response to atenolol (P=3.3×10-6 for systolic BP; P=1.6×10-6 for diastolic BP). The genetic score of the hydrochlorothiazide BP-lowering alleles was associated with response to hydrochlorothiazide (P=0.0006 for systolic BP; P=0.0003 for diastolic BP). Both risk score P values were <0.01 based on the empirical distribution from the permutation test. Conclusions-These findings suggest that selected signals from hypertension genome-wide association studies may predict BP response to atenolol and hydrochlorothiazide when assessed through risk scoring.

KW - β-blocker

KW - Blood pressure

KW - Diuretics

KW - Hypertension

KW - Pharmacogenetics

KW - Polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=84873913555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873913555&partnerID=8YFLogxK

U2 - 10.1161/CIRCGENETICS.112.964080

DO - 10.1161/CIRCGENETICS.112.964080

M3 - Article

C2 - 23087401

AN - SCOPUS:84873913555

VL - 5

SP - 686

EP - 691

JO - Circulation. Genomic and precision medicine

JF - Circulation. Genomic and precision medicine

SN - 1942-325X

IS - 6

ER -